Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Sells Nutrition Branch for $4.6M

NEW YORK (GenomeWeb News) – Interleukin Genetics said today that it has sold its Alan James Group business to Pep Products, a subsidiary of Nutraceutical Corporation, for around $4.6 million in cash.

The Alan James Group is based in Boca Raton, Fla., and it markets nutritional supplements.

"While the Alan James Group business saw an increase in sales during the last fiscal year and we were able to introduce two new products in the last seven months, this transaction allows us to focus our efforts on growing our core genetic testing business," said Interleukin Genetics CEO, Lewis Bender.

The sale of AJG provides non-dilutive cash to continue development and promotion of our genetic testing services and products including our new brand of Inherent Health tests," Bender added.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.